Premium
Increased fetal nuchal translucency at 11–14 weeks
Author(s) -
Nicolaides Kypros H.,
Heath Victoria,
Cicero Simona
Publication year - 2002
Publication title -
prenatal diagnosis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.956
H-Index - 97
eISSN - 1097-0223
pISSN - 0197-3851
DOI - 10.1002/pd.308
Subject(s) - trisomy , nuchal translucency , medicine , nuchal translucency measurement , fetus , pregnancy associated plasma protein a , down syndrome , obstetrics , aneuploidy , monochorionic twins , neonatology , genetic syndromes , turner syndrome , pregnancy , prenatal diagnosis , pediatrics , biology , first trimester , chromosome , biochemistry , genetics , psychiatry , gene
Nuchal translucency (NT) is the sonographic appearance of a subcutaneous collection of fluid behind the fetal neck. The measurement of fetal NT thickness at the 11–14‐week scan has been combined with maternal age to provide an effective method of screening for trisomy 21; for an invasive testing rate of 5%, about 75% of trisomic pregnancies can be identified. When maternal serum free‐β human chorionic gonadotrophin (β‐hCG) and pregnancy‐associated plasma protein‐A (PAPP‐A) at 11–14 weeks are also taken into account, the detection rate of chromosomal defects is about 90%. Increased NT can also identify a high proportion of other chromosomal abnormalities and is associated with major defects of the heart and great arteries, and a wide range of skeletal dysplasias and genetic syndromes. In monochorionic twins, discordancy for increased NT is an early marker of twin‐to‐twin transfusion syndrome (TTTS). As with the introduction of any new technology into routine clinical practice, it is essential that those undertaking the 11–14‐week scan are adequately trained and their results are subjected to rigorous audit. Copyright © 2002 John Wiley & Sons, Ltd.